Citius Pharmaceuticals, Inc. (CTXR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.56

From 52W high−60.43%

Volume60007.00

Market cap$15.64M

P/E (TTM)—

P/S (TTM)2.2x

Div yield—

Key dataNov 4, 2026

Open

$0.56

From 52W high

−60.43%

Volume

60007.00

Market cap

$15.64M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

—

RSI (14)

58.0

MomentumView details →

1D Return

−0.59%

YTD Return

−27.94%

SummaryUpdated Jun 1, 2026

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company founded in 2007 and headquartered in Cranford, New Jersey. The company went public in October 2014 and focuses on developing critical care products, particularly anti-infective treatments for cancer care, prescription therapeutics, and advanced stem cell therapies. As a clinical-stage biotechnology company, Citius has built a pipeline of five proprietary products targeting various medical conditions, from catheter-related infections to cancer treatments, though it has yet to generate substantial commercial revenues from these developments.

Ask drillr about Citius Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.3x

EV/Sales

2.1x

P/S (TTM)

2.2x

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

19.97%

Net Margin

−651.27%

EBITDA Margin

−804.88%

ROE (TTM)

−69.47%

ROA (TTM)

−32.53%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

+4456.78%

EPS YoY

+57.46%

FCF YoY

−69.38%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+43.38%

EBITDA YoY

−39.83%

MomentumView details →

1D Return

−0.59%

YTD Return

−27.94%

1Y Return

−59.13%

RSI (14)

58.0

vs 50D SMA

+4.90%

vs 200D SMA

−14.23%

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

0.84x

Quick Ratio

0.40x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

5.56%

Beats (12Q)

2/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

−137.43%

Rev Surprise

−72.64%

Financials snapshotView financials →

Revenue (TTM)

7.11M

Net Income (TTM)

−46.27M

Op. CF (TTM)

−34.87M

Next earningsDec 29, 2026 →

Latest newsMore news →

Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, with $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and $17 million in cash and cash equivalents as of June 30, 2026.82d ago

Similar companies

Hoth Therapeutics, Inc.HOTH Acumen Pharmaceuticals, Inc.ABOS Jasper Therapeutics, Inc.JSPR NewcelX Ltd.NCEL Pluri Inc.PLUR Tevogen Bio Holdings Inc.TVGNW Find similar companies →

Latest newsMore news →

Citius Pharmaceuticals, Inc. reported preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026, with shipments of LYMPHIR units to U.S. wholesalers up 120%.9d ago Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, with $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and $17 million in cash and cash equivalents as of June 30, 2026.82d ago